<DOC>
	<DOCNO>NCT01079364</DOCNO>
	<brief_summary>Primary Objective : To demonstrate non-inferiority daily injection insulin glargine ( Lantus ) plus one injection mealtime insulin glulisine ( Apidra ) main meal versus twice daily premixed insulin ( NovoMix 30/70 ) base reduction HbA1c percentage baseline endpoint . Secondary Objective : - To determine treatment satisfaction ( DTSQs/Diabetes Treatment Questionnaire - Status , DTSQc/ Diabetes Treatment Questionnaire - change ITSQ/Insulin Treatment Satisfaction Questionnaire ) - To determine mean HbA1c , FBG ( Fasting Blood Glucose ) , prandial BG ( Blood Glucose ) proportion patient HbA1c &lt; 7 % - To determine effect adverse event ( e.g . symptomatic hypoglycemic event , weight gain injection site reaction ) - To determine total insulin dose , average insulin glargine , insulin glulisine premixed insulin dosage .</brief_summary>
	<brief_title>Better Acceptance Single Injection Apidra Added Once Daily Lantus Versus Twice Daily Premixed Insulin Real Life Use Setting</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes mellitus treat insulin glargine daily oral blood glucose lower medication Patients HbA1c &gt; 7 % Patients FBG within range ( 47 mmol/L ) baseline , base mean 3 FBG value ( measure 5x runin phase , high low value exclude ) Exclusion criterion : Patients treat insulin insulin glargine Patients hypersensitivity insulin glargine , insulin glulisine , biphasic insulin aspart/insulin aspart protamine 30/70 excipients Patients ( pre ) proliferative retinopathy ( optic fundus examination perform within 2 year prior study entry ) Pregnant lactate woman Patients unable fill PRO ( Patient Reported Outcomes ) questionnaires The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>